With a portfolio approaching 200 products, CDMO WuXi Biologics has begun constructing a 1.6 million square-foot facility in Shanghai, China.
Contract development and manufacturing organization (CDMO) WuXi Biologics is building what it calls a ‘Biologics Innovation Center’ in Fengxian, Shanghai. The 1.6 million square-foot facility will include biologics discovery and development laboratories, as well as GMP manufacturing, CEO Chris Chen told BioProcessing Insider.
He added the labs will open in 2019, while the GMP plant will open its doors in 2021, though for now the planned “significant†capacity has not been disclosed.
China’s WuXi Biologics is building another plant to deal with growing biomanufacturing services demand. Image: iStock/liulolo
WuXi has been rapidly expanding over the past few years, and this latest project will become the twelfth biomanufacturing plant in the firm’s network. Earlier this year, the CDMO announced it was constructing two facilities in Shijiazhuang, China with a total of 52,500 L of single-use capacity, set to become its sixth and seventh Chinese facility.
The firm has also begun taking steps outside its native China, announcing facilities in Ireland, Singapore, and Massachusetts (US) over the past seven months.
According to Chen, the rapid expansion is required to deal with the growing demand for biologics manufacturing and services the firm is seeing. “We have a portfolio of 187 biologics that need manufacturing, and the number of projects is still growing.â€
Once complete, the Fengxian site will hire more than 3,000 scientists, most of which will be sourced from China.
WuXi Biologic’s Global Network
| Â | DS Capacity | GMP Ready | Location | Clinical/Commercial |
| MFG1 | 5,000 L fed-batch/perfusion | 2012 | Wuxi, China | Commercial |
| MFG2 | 28,000 L fed-batch
2,000 L perfusion |
2017 | Wuxi, China | Commercial |
| MFG3 | 5,200 L fed-batch | 2018 | Shanghai, China | Clinical |
| MFG4 | 10,000 L fed-batch | 2019 | Wuxi, China | Clinical/Commercial |
| MFG5 | 60,000 L fed-batch | 2020 | Wuxi, China | Commercial |
| MFG6 | 6 x 1,000 L perfusion | 2021 | Mullagharlin, Ireland | Commercial |
| MFG7 | 48,000 L fed-batch | 2021 | Mullagharlin, Ireland | Commercial |
| MFG8 | 48,000 L fed-batch | 2021 | Shijiazhuang, China | Commercial |
| MFG9 | 4,500 L fed-batch/perfusion | 2022 | Shijiazhuang, China | Clinical/Commercial |
| MFG10 | 4,500 L fed-batch/perfusion | 2022 | Singapore | Clinical/Commercial |
| MFG11 | 4,500 L fed-batch/perfusion | 2020 | Massachusetts, US | Clinical/Commercial |
| MFG12 |  ‘Biologics Innovation Center,’ undisclosed capacity | 2021 | Fengxian, Shanghai, China | Clinical/Commercial |